

Research and Reviews: Journal of Botanical Sciences

A Review on Pharmacological Profile of *Withania somnifera* (Ashwagandha).

Kaur Narinderpal^{1*}, Niazi Junaid², and Bains Raman³

¹Baddi University of Emerging Sciences and Technology, Makhnumajra, Baddi - 173205, Himachal Pradesh, India.

²Bahra Institute of Pharmacy, Patiala - 147001, Punjab, India.

³Grecian Superspeciality Hospital, Sector-69, SAS Nagar, Mohali, Punjab, India.

Review Article

Received: 07/08/2013

Revised: 17/09/2013

Accepted: 01/10/2013

*For Correspondence

Baddi University of Emerging Sciences and Technology, Makhnumajra, Baddi - 173205, Himachal Pradesh, India.

Keywords: *Withania somnifera*, Withanolides, Pharmacological activities.

ABSTRACT

Withania somnifera (Ashwagandha) is a plant used in medicine from the time of Ayurveda, the ancient system of Indian medicine. The dried roots of the plant are used in the treatment of nervous and sexual disorders. This review article is presented to compile all the updated information on its phytochemical and pharmacological activities, which were performed by widely different methods. Studies indicate ashwagandha possesses antioxidant, anxiolytic, adaptogen, memory enhancing, antiparkinsonian, antivenom, antiinflammatory, antitumor properties. Various other effects like immunomodulation, hypolipidemic, antibacterial, cardiovascular protection, sexual behaviour, tolerance and dependence have also been studied. These results are very encouraging and indicate this herb should be studied more extensively to confirm these results and reveal other potential therapeutic effects. Clinical trials using ashwagandha for a variety of conditions should also be conducted.

INTRODUCTION

Withania somnifera (WS), also known as ashwagandha, Indian ginseng, and winter cherry, it has been an important herb in the Ayurvedic and indigenous medical systems for over 3000 years. The roots of the plant are categorised as rasayanans, which are reputed to promote health and longevity by augmenting defence against disease, arresting the ageing process, revitalising the body in debilitated conditions, increasing the capability of the individual to resist adverse environmental factors and by creating a sense of mental wellbeing [1]. It is in use for a very long time for all age groups and both sexes and even during pregnancy without any side effects [2]. The pharmacological effects of the roots of WS are attributed to the presence of withanolides, a group of steroidal lactones [3]. Its leaves are used in Ayurvedic and Unani systems for treatment of tumors and tubercular glands [4]. A number of withanolide steroidal lactones have been isolated from the leaves of *W. somnifera* [5]. and exhibit antibacterial, anti-fungal and antitumor properties [6]. Ashwagandha is used to calm the mind, relieve weakness and nervous exhaustion, build sexual energy and promote healthy sleep. The herb is termed a rasayana. in Ayurvedic practice, which means it acts as a tonic for vitality and longevity. It is also classified as an adaptogen [7]. Two varieties of Asgand have been mentioned in classical Unani literature: 1) Asgand Nagori and 2) Asgand Dakani. Asgand Nagori is preferred for its more potential medicinal properties [8].

Taxonomical Classification

Kingdom : Plantae, Plants;
Subkingdom : Tracheobionta, Vascular plants;
Super division : Spermatophyta, Seeds plants;
Division : Angiosperma
Class : Dicotyledons


Order : Tubiflorae
Family : Solanaceae
Genus : Withania
Species : somnifera Dunal

Botanical Description

WS is a small, woody shrub in the Solanaceae family that grows about two feet in height. It can be found growing in Africa, the Mediterranean, and India. An erect, evergreen, tomentose shrub, 30-150 cm high, found throughout the drier parts of India in waste places and on bunds. Roots are stout fleshy, whitish brown; leaves simple ovate, glabrous, those in the floral region smaller and opposite; flowers inconspicuous, greenish or lubrid-yellow, in axillary, umbellate cymes; berries small, globose, orange-red when mature, enclosed in the persistent calyx; seeds yellow, reniform. The roots are the main portions of the plant used therapeutically. The bright red fruit is harvested in the late fall and seeds are dried for planting in the following spring. Parts used: Whole plant, roots, leaves, stem, green berries, fruits, seeds, bark are used.

Chemical Composition

Laboratory analysis has revealed over 35 chemical constituents contained in the roots of *Withania somnifera* [9]. The biologically active chemical constituents are alkaloids (isopelletierine, anferine), steroidal lactones (withanolides, withaferins), saponins containing an additional acyl group (sitoindoside VII and VIII), and withanoloides with a glucose at carbon 27 (sitonidoside XI and X). *Withania somnifera* is also rich in iron. The roots of *Withania somnifera* consist primarily of compounds known as withanolides, which are believed to account for its extraordinary medicinal properties. Withanolides are steroidal and bear a resemblance, both in their action and appearance, to the active constituents of Asian ginseng (*Panax ginseng*) known as ginsenosides. Ashwagandha's withanolides have been researched in a variety of animal studies examining their effect on numerous conditions, including immune function and even cancer [10]. Chemical analysis of Ashwagandha show its main constituents to be alkaloids and steroidal lactones. Among the various alkaloids, withanine is the main constituent. The other alkaloids are somniferine, somniferinine, withananine, pseudo-withanine, tropine, pseudo-tropine, 3-a-gloyloxytropine, choline, cuscohygrine, isopelletierine, anaferine and anahydrine. Two acyl steryl glucoside viz. sitoindoside VII and sitoindoside VIII have been isolated from root. The leaves contain steroidal lactones, which are commonly called withanolides. The withanolides have C28 steroidal nucleus with C9 side chain, with a six membered lactone ring [11]. Twelve alkaloids, 35 withanolides, and several sitoindosides from *Withania somnifera* have been isolated and studied. Asitoinidoside is a withanolide containing a glucose molecule at carbon 27. Much of Ashwagandha's pharmacological activity has been attributed to two main withanolides, withaferin A and withanolide D. Further chemical analysis has shown the presence of the following: Anaferine (Alkaloid), Anahygrine (Alkaloid), Beta-Sisterol, Chlorogenic acid (in leaf only), Cysteine (in fruit), Cuscohygrine (Alkaloid), Iron, Pseudotropine (Alkaloid), Scopoletin, Somniferinine (Alkaloid), Somniferiene (Alkaloid), Tropanol (Alkaloid), Withanine (Alkaloid), Withananine (Alkaloid) and Withanolides A-Y (Steroidal lactones) [12,13].



Pharmacological Activity

Centuries of Ayurvedic medical experience using *Withania somnifera* have revealed it to have pharmacological value as an adaptogen, antibiotic,

aboritifacient, aphrosidiac, astringent, antiinflammatory, deobstruent, diuretic, narcotic, sedative, and tonic. Ashwagandha has been found to: Provide potent antioxidant protection [14,15]. Stimulate the activation of immune system cells, such as lymphocytes and phagocytes [16,17]. Counteract the effects of stress and generally promote wellness [18].

Anti-inflammatory Activity

Withaferin A exhibits fairly potent anti-arthritic and anti-inflammatory activities. Anti-inflammatory activity has been attributed to biologically active steroids, of which Withaferin A is a major component. It is as effective as hydrocortisone sodium succinate dose for dose [19]. It was found to suppress effectively arthritic syndrome without any toxic effect. Unlike hydrocortisone-treated animals which lost weight, the animals treated with Withaferin A showed gain in weight in arthritic syndrome. It is interesting that Withaferin A seems to be more potent than hydrocortisone in adjuvant-induced arthritis in rats, a close experimental approximation to human rheumatoid arthritis. In its oedema inhibiting activity, the compound gave a good doseresponse in the dose range of 12-25 mg/kg body weight of Albino rats intraperitoneally and a single dose had a good duration of action, as it could effectively suppress the inflammation after 4 hours of its administration [20]. Asgand (*Withania somnifera*) has been shown to possess anti-inflammatory property in many animal models of inflammations like carrageenan-induced inflammation, cotton pellet granuloma and adjuvant-induced arthritis. Detailed studies were carried out to investigate the release of serum β -1 globulin during inflammation by two models of inflammations viz. primary phase of adjuvant-induced arthritis and formaldehyde-induced arthritis. The experiments showed interesting results as most of the APR were influenced in a very short duration and also suppressed the degree of inflammation [21].

Anti-stress

A study conducted by the Institute of Basic Medical Sciences at Calcutta University examined the effects of Ashwagandha on chronic stress in rodents. For a period of 21 days, the animals received a mild electric shock to their feet. The resulting stress on the animals produced hyperglycemia, glucose intolerance, increase in plasma corticosterone levels, gastric ulcerations, male sexual dysfunction, cognitive deficits, immunosuppression and mental depression [22]. Researchers using *Withania somnifera* discovered the animals given the herb an hour before the foot shock experienced a significantly reduced level of stress. This research confirms the theory that Ashwagandha has a significant anti-stress adaptogenic effect [23]. Research conducted at the Department of Pharmacology, University of Texas Health Science Center indicated that extracts of Ashwagandha produce GABA-like activity, which may account for the herb's anti-anxiety effects [24]. GABA (Gamma Amino-butyric acid) is an inhibitory neurotransmitter in the brain. Its function is to decrease neuron activity and inhibit nerve cells from over firing. This action produces a calming effect. Excessive neuronal activity can lead to restlessness and insomnia, but GABA inhibits the number of nerve cells that fire in the brain, and helps to induce sleep, uplift mood, and reduce anxiety. Ashwagandha has traditionally been used to stabilize mood in patients with behavioral disturbances. Research has revealed that the herb produces an anti-depressant and anti-anxiety effect in rodents comparable to the anti-depressant drug imipramine and the anti-anxiety drug lorazepam (Ativan) [25]. In fact, Ashwagandha is one of the most widespread tranquilizers used in India, where it holds a position of importance similar to ginseng in China. It acts mainly on the reproductive and nervous systems, having a rejuvenative effect on the body, and is used to improve vitality and aid recovery after chronic illness [26]. Chronic stress can cause conditions such as cognitive deficit, immunosuppression, sexual dysfunction, gastric ulceration, irregularities in glucose homeostasis, and changes in plasma corticosterone levels. In a rat model of chronic stress syndrome, *Withania somnifera* and *Panax ginseng* extracts were compared and contrasted for their abilities to relieve some of the adverse effects of chronic stress [27]. Research results showed that both Ashwagandha and *Panax ginseng* decreased the frequency and severity of stress-induced ulcers, reversed stress-induced inhibition of male sexual behavior, and inhibited the effects of chronic stress on retention of learned tasks. Both botanicals also reversed stress-induced immunosuppression, but only the *Withania* extract increased peritoneal macrophage activity. The activity of the *Withania* extract was about the same as the activity of the *ginseng* extract. *Withania somnifera*, however, has an advantage over *Panax ginseng* in that it does not appear to result in .ginseng-abuse syndrome., a condition characterized by high blood pressure, water retention, muscle tension, and insomnia [28].

Antibiotic Activity

The antibiotic activity of the roots as well as leaves has recently been shown experimentally. Withaferin A in concentration of 10 μ g/ml inhibited the growth of various Gram-positive bacteria, acid-fast and aerobic bacilli, and pathogenic fungi. It was active against *Micrococcus pyogenes* var *aureus* and partially inhibited the activity of *Bacillus subtilis* glucose-6-phosphatedehydrogenase. Withaferin A inhibited Ranikhet virus. The shrub's extract is active against *Vaccinia* virus and *Entamoeba histolytica* [29]. Asgand showed the protective action against systemic *Aspergillus*

infection. This protective activity was probably related to the activation of the macrophage function revealed by the observed increases in phagocytosis and intracellular killing of peritoneal macrophages induced by Ashwagandha treatment in mice ^[30]. Antibiotic activity of Withaferin A is due to the presence of the unsaturated lactone-ring. The lactone showed strong therapeutic activity in experimentally induced abscesses in rabbits, the being somewhat stronger than that of Penicillin. It substantiates the reputation of the leaves as a cure for ulcers and carbuncles in the indigenous system of medicine ^[31].

Antioxidant effect

The brain and nervous system are relatively more susceptible to free radical damage than other tissues because they are rich in lipids and iron, both known to be important in generating reactive oxygen species. Free radical damage of nervous tissue may be involved in normal aging and neurodegenerative diseases, e.g., epilepsy, schizophrenia, Parkinson's, Alzheimer's, and other diseases. The active principles of WS, sitoindosides VII-X and withaferin A (glycowithanolides), have been tested for antioxidant activity using the major free-radical scavenging enzymes, superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) levels in the rat brain frontal cortex and striatum. Decreased activity of these enzymes leads to accumulation of toxic oxidative free radicals and resulting degenerative effects. An increase in these enzymes would represent increased antioxidant activity and a protective effect on neuronal tissue. Active glycowithanolides of WS were given once daily for 21 days, dose-related increases in all enzymes were observed; the increases comparable to those seen with deprenyl (a known antioxidant) administration. This implies that WS does have an antioxidant effect in the brain, which may be responsible for its diverse pharmacological properties ^[32]. In another study, an aqueous suspension of WS root extract was evaluated for its effect on stress-induced lipid peroxidation (LPO) in mice and rabbits. LPO blood levels were increased by lipopolysaccharides (LPS) from *Klebsiella pneumoniae* and peptidoglycans (PGN) from *Staphylococcus aureus*. Simultaneous oral administration of WS extract prevented an increase in LPO ^[33]. Apart from hepatic lipid peroxidation (LPO), the serum enzymes, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase, were assessed as indices of hepatotoxicity. Silymarin (20 mg/kg, p.o.) was used for comparison. Iron overload induced marked increase in hepatic LPO and serum levels of the enzymes, which was attenuated by glycowithanolides (WSG) in a dose-related manner, and by silymarin ^[34].

Anti-aging activity

Ashwagandha was tested for its anti-aging properties in a double-blind clinical trial. A group of 101 healthy males, 50-59 years old were given the herb at a dosage of 3 grams daily for one year. The subjects experienced significant improvement in hemoglobin, red blood cell count, hair melanin, and seated stature. Serum cholesterol decreased and nail calcium was preserved. Seventy percent of the research subjects reported improvement in sexual performance ^[35].

Anticonvulsant Activity

Administration of Ashwagandha root extract was found to reduce jerks and clonus in 70% and 10% animals respectively with dose of 100mg/kg and reduction in the severity of pentylenetetrazole (PTZ)-induced convulsions was evident from EEG wave pattern ^[36]. Ashwagandha root extract showed reduction in severity of motor seizures induced by electrical stimulation in right basilateral amygdaloid nuclear complex through bipolar electrodes. The protective effect of Ashwagandha extract in convulsions has been reported to involve GABAergic mediation ^[37].

Nootropic effect

Effects of sitoindosides VII-X and withaferin isolated from aqueous methanol extract of roots of cultivated varieties of WS were studied on brain cholinergic, glutamatergic and GABAergic receptors in rats. The compounds slightly enhanced acetylcholinesterase (AChE) activity in the lateral septum and globus pallidus, and decreased AChE activity in the vertical diagonal band. These changes were accompanied by enhanced M1-muscarinic-cholinergic receptor binding in lateral and medial septum as well as in frontal cortices, whereas the M2-muscarinic receptor-binding sites were increased in a number of cortical regions including cingulate, frontal, parietal, and retrosplenial cortex. The data suggest the compounds preferentially affect events in the cortical and basal forebrain cholinergic-signal transduction cascade. The drug-induced increase in cortical muscarinic acetylcholine receptor capacity might partly explain the cognition-enhancing and memory-improving effects of WS extracts in animals and in humans ^[38]. In a study by Zhao et al ^[39] Withanoside IV (a constituent of WS; the root of WS) induced neurite outgrowth in cultured rat cortical neurons. Oral administration of withanoside IV significantly improved

memory deficits in Abeta-injected mice and prevented loss of axons, dendrites, and synapses. Sominone, an aglycone of withanoside IV, was identified as the main metabolite after oral administration of withanoside IV. Sominone induced axonal and dendritic regeneration and synaptic reconstruction significantly in cultured rat cortical neurons damaged by Abeta. Withanoside IV may ameliorate neuronal dysfunction in Alzheimer's disease and that the active principle after metabolism is sominone. In another study reserpine treated animals also showed poor retention of memory in the elevated plus maze task paradigm. Chronic WS administration significantly reversed reserpine-induced retention deficits [40]. In different study with WS root extract improved retention of a passive avoidance task in a step-down paradigm in mice. WS also reversed the scopolamine-induced disruption of acquisition and retention and attenuated the amnesia produced by acute treatment with electroconvulsive shock (ECS), immediately after training. Chronic treatment with ECS, for 6 successive days at 24 h intervals, disrupted memory consolidation on day 7. Daily administration of WS for 6 days significantly improved memory consolidation in mice receiving chronic ECS treatment. WS, administered on day 7, also attenuated the disruption of memory consolidation produced by chronic treatment with ECS. On the elevated plus-maze, WS reversed the scopolamine-induced delay in transfer latency on day 1. On the basis of these findings, it is suggested that WS exhibits a nootropic-like effect in naïve and amnesic mice [41].

Antiparkinsonian properties

Parkinson's disease is a neurodegenerative disease characterized by the selective loss of dopamine (DA) neurons of the substantia nigra pars compacta. The events, which trigger and/or mediate the loss of nigral DA neurons, however, remain unclear. Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism. Administration of haloperidol or reserpine significantly induced catalepsy in mice. WS significantly inhibited haloperidol or reserpine-induced catalepsy and provide hope for treatment of Parkinson's disease [42]. In another study, 6-Hydroxydopamine (6-OHDA) is one of the most widely used rat models for Parkinson's disease. There is ample evidence in the literature that 6-OHDA elicits its toxic manifestations through oxidant stress. Antiparkinsonian effects of WS extract has been reported due to potent antioxidant, antiperoxidative and free radical quenching properties in various diseased conditions. Rats were pretreated with the WS extract orally for 3 weeks. On day 21, 6-OHDA was infused into the right striatum while sham operated group received the vehicle. Three weeks after 6-OHDA injections, rats were tested for neurobehavioral activity and were killed 5 weeks after lesioning for the estimation of lipidperoxidation, reduced glutathione content, activities of glutathione-S-transferase, glutathione reductase, GPX, SOD and CAT, catecholamine content, dopaminergic D2 receptor binding and tyrosine hydroxylase expression. WS extract reversed all the parameters significantly in a dose-dependent manner [43]. Tardive dyskinesia is one of the major side effects of long-term neuroleptic treatment. The pathophysiology of this disabling and commonly irreversible movement disorder is still obscure. Vacuous chewing movements in rats are widely accepted as an animal model of tardive dyskinesia. Oxidative stress and products of lipid peroxidation are implicated in the pathophysiology of tardive dyskinesia. Repeated treatment with reserpine on alternate days for a period of 5 days significantly induced vacuous chewing movements and tongue protrusions in rats. Chronic treatment with WS root extract for a period of 4 weeks to reserpine treated animals significantly and dose dependently reduced the reserpine-induced vacuous chewing movements and tongue protrusions. Oxidative stress might play an important role in the pathophysiology of reserpine-induced abnormal oral movements [44]. In another study, WS glycowithanolides (WSG) administered concomitantly with haloperidol for 28 days, inhibited the induction of the neuroleptic TD. Haloperidol-induced TD was also attenuated by the antioxidant, vitamin E, but remained unaffected by the GABA-mimetic antiepileptic agent, sodium valproate, both agents being administered for 28 days like WSG. Antioxidant effect of WSG, rather than its GABA-mimetic action reported for the prevention of haloperidol-induced TD [45]. WS significantly reversed the catalepsy, tardive dyskinesia and 6- Hydroxydopamine elicited toxic manifestations and may offer a new therapeutic approach to the treatment of Parkinson's disease.

Cardiovascular protection

WS may be useful as a general tonic, due in part to its beneficial effects on the cardiopulmonary system, as reported in the following studies. The effect of WS was studied on the cardiovascular and respiratory systems in dogs and frogs [46]. The alkaloids had a prolonged hypotensive, bradycardiac, and respiratory stimulant action in dogs. The study found that the hypotensive effect was mainly due to autonomic ganglion blocking action and that a depressant action on the higher cerebral centers also contributed to the hypotension. The alkaloids stimulated the vasomotor and respiratory centers in the brain stem of dogs. The cardio-inhibitory action in dogs appeared to be due to ganglion blocking and direct cardiodepressant actions. The alkaloids produced immediate predominant but short-lived cardio-depressant effects and a weak but prolonged cardiostimulant effect in isolated normal and hypodynamic frog hearts. In another study, Left ventricular dysfunction was seen as a decrease in heart rate, left ventricular rate of peak positive and negative pressure change and elevated left ventricular end-diastolic pressure in the control group was recorded. WS showed strong cardioprotective effect in the experimental model of isoprenaline-induced myonecrosis in rats.

Augmentation of endogenous antioxidants, maintenance of the myocardial antioxidant status and significant restoration of most of the altered haemodynamic parameters may contribute to its cardioprotective effect [47].

Immunomodulatory Activity

Asgand showed a significant modulation of immune reactivity in animal models. Administration of Asgand was found to prevent myelo-suppression in mice treated with three immunosuppressive drugs viz. cyclophosphamide, azathioprin, and prednisolone. Treatment with Asgand was found to significantly increase Hb concentration, RBC count, platelet count, and body weight in mice [48]. Administration of Asgand extract was found to significantly reduce leucopenia induced by cyclophosphamide (CTX) treatment. Administration of Asgand extract increased the number of β -esterase positive cells in the bone marrow of CTX treated animals, compared to the CTX alone treated group [44]. Administration of Asgand extract was found to significantly reduce leucopenia induced by sub-lethal dose of gamma radiation [49]. Withaferin A and Withanolide E exhibited specific immunosuppressive effect on human B and T lymphocytes and on mice thymocytes. Withanolide E had specific effect on T lymphocytes whereas Withaferin A affected both B and T lymphocytes [50].

Anti-hyperglycaemic Effect

Asgand along with other ingredients of a composite formulation (Transina) have been reported to decrease streptozocin (STZ)-induced hyperglycaemia in rats. This anti-hyperglycaemic effect may be due to pancreatic islet free radical scavenging activity because the hyperglycaemic activity of STZ is a consequence of decrease in pancreatic islet cell superoxide dismutase (SOD) activity leading to the accumulation of degenerative oxidative free radicals in islet-beta cells [51].

Hypolipidemic effect

WS root powder decreased total lipids, cholesterol and triglycerides in hypercholesteremic animals. On the other hand, significantly increased plasma HDL-cholesterol levels, HMG-CoA reductase activity and bile acid content of liver. A similar trend also reported in bile acid, cholesterol and neutral sterol excretion in the hypercholesteremic animals with WS administration. Further, a significant decrease in lipid-peroxidation occurred in WS administered hypercholesteremic animals when compared to their normal counterparts. However, WS root powder was also effective in normal subjects for decreasing lipid profiles [52]. In another study with aqueous extract of fruits of *Withania coagulans* to high fat diet induced hyperlipidemic rats for 7 weeks, significantly reduced elevated serum cholesterol, triglycerides and lipoprotein levels. This drug also showed hypolipidemic activity in triton-induced hypercholesterolemia. The histopathological examination of liver tissues of treated hyperlipidemic rats showed comparatively lesser degenerative changes compared with hyperlipidemic controls. The hypolipidemic effect of *Withania coagulans* fruits reported to be comparable to that of an Ayurvedic product containing *Commiphora mukul* [53]. In another study, hypoglycemic, diuretic and hypocholesterolemic effects of roots of WS were assessed on human subjects. Six mild NIDDM subjects and six mild hypercholesterolemic subjects were treated with the powder of roots of WS for 30 days. Suitable parameters were studied in the blood and urine samples of the subjects along with dietary pattern before and at the end of treatment period. Decrease in blood glucose was comparable to that of an oral hypoglycemic drug. Significant increase in urine sodium, urine volume, significant decrease in serum cholesterol, triglycerides, LDL (low density lipoproteins) and VLDL (very low density lipoproteins) cholesterol were observed indicating that root of WS is a potential source of hypoglycemic, diuretic and hypocholesterolemic agents [54].

Sexual behavior

Methanolic root extract of WS were orally administered at dose 3000 mg/kg/day of 7 days in rats. Their sexual behaviour was evaluated 7 days prior to treatment, day 3 and 7 of treatment, and day 7, 14 and 30 post-treatment by pairing each male with a receptive female. The WS root extract induced a marked impairment in libido, sexual performance, sexual vigour, and penile erectile dysfunction. These effects were partly reversible on cessation of treatment. This antimasculine effect was not due to changes in testosterone levels but attributed to hyperprolactinemic, GABAergic, serotonergic or sedative activities of the extract. WS roots may be detrimental to male sexual competence [55].

Anti-carcinogenic activity

Ashwagandha is reported to have anti-carcinogenic effects. Research on animal cell cultures has shown that the herb decreases the levels of the nuclear factor kappaB, suppresses the intercellular tumor necrosis factor, and potentiates apoptotic signalling in cancerous cell lines [56]. One of the most exciting of the possible uses of Ashwagandha is its capacity to fight cancers by reducing tumor size [57, 58]. To investigate its use in treating various forms of cancer, the antitumor effects of *Withania somnifera* have been studied by researchers. In one study, the herb was evaluated for its anti-tumor effect in urethane-induced lung tumors in adult male mice [59]. Following administration of Ashwagandha over a period of seven months, the histological appearance of the lungs of animals which received the herb was similar to those observed in the lungs of control animals.

Other Therapeutic Benefits

Further studies have also shown ashwagandha to be effective in the treatment of osteoarthritis, [60] inflammation [61], stroke [62], and tardive dyskinesia [63]. Ashwagandha has been shown to be a potential antimicrobial agent, with antifungal activity [64], and moderate antibacterial activity against *Staphylococcus aureus* and *Pseudomonas Aeruginosa* bacteria strains [65].

CONCLUSION

Withania somnifera (Ashwagandha) is a plant used in medicine from the time of Ayurveda, the ancient system of Indian medicine. The plant has also been widely studied for their various pharmacological activities like antioxidant, anxiolytic, adaptogen, memory enhancing, antiparkinsonian, antiinflammatory, antitumor properties. Various other effects like immunomodulation, hypolipidemic, antibacterial, cardiovascular protection, sexual behaviour, have also been studied. Although the results from this review are quite promising for the use of WS as a multi-purpose medicinal agent, several limitations currently exist in the current literature. While WS has been used successfully in Ayurvedic medicine for centuries, more clinical trials should be conducted to support its therapeutic use.

REFERENCES

1. Weiner, M.A, Weiner.J Ashwagandha (India ginseng). In: Herbs that Heal. Mill Valley, CA: Quantum Books,70–72;1994.
2. S. Sharma, S. Dahanukar, S.M. Karandikar. Effects of long-term administration of the roots of ashwagandha and shatavari in rats. Indian Drugs. 1985;133–139.
3. Budhiraja RD, Sudhir S. Review of biological activity of Withenolides (Antibacterial Antitumor, Immunomodulating, Antiinflammatory and insect anti feedcent). J Sci Ind Res. 46, 488-91.
4. Chopra, R.N. Glossary of Indian Medicinal Plants. New Delhi: Academic Publishers India; 1994.
5. Glotter E, Kirson I, Abraham A, Lavie D. Constituents of *Withania somnifera* Dun–13. The withanolides of chemotype III. Tetrahedron. 1973;29(10):1353–1364.
6. Devi PU, Sharada AC, Solomon FE. Antitumor and radiosensitizing effects of *Withania somnifera* (Ashwagandha) on a transplantable mouse tumor, Sarcoma- 180. Indian J Exp Biol. 1993;31(7):607-11
7. "Withania somnifera". Alternative Medicine Review. FindArticles.com. 13 Oct. 2008.
8. Behl PN, Arora RB, Srivastava and Malhotra SC. Herbs Useful in Dermatological Therapy.;New Delhi :CBS Publishers and Distributors, 141-142; 1993.
9. Rastogi RP, Mehrotra BN, Compendium of Indian Medicinal Plants, Central Drug Research Institute, New Delhi, Vol. 6;1998.
10. Grandhi, A. Comparative pharmacological investigation of ashwagandha and Ginseng. J Ethnopharmacol (Ireland).1994;3:131-135.
11. Dr. Ajay Padmawar; *Withania somnifera*. Monograph for Anruta Herbals, LTD.
12. Bone K; Clinical Applications of Ayurvedic and Chinese Herbs. Queensland, Australia: Phytotherapy Press; 137-41; 1996..
13. Elsakka M, Grigorescu E, Stanescu U et al. New data referring to chemistry of *Withania somnifera* species. Rev Med Chir Soc Med Nat Iasi. 1990;94:385-387.
14. Abou-Douh AM. New withanolides and other constituents from the fruit of *Withania somnifera*. Arch Pharm. 2002;335:267-76.
15. Panda S, Kar A. Evidence for free radical scavenging activity of Ashwagandha root powder in mice Indian J Physiol Pharmacol. 1997;424-426.
16. Wagner H, Norr H, Winterhoff H. Plant adaptogens, Phytomed 1994;63-76.

17. Singh B, Saxena AK, Chandan BK et al. Adaptogenic activity of a novel, withanolide-free aqueous fraction from the roots of *Withania somnifera* Dun. *Phytother Res.* 2001;15:311-318.
18. Singh B, Chandan BK, Gupta DK. Adaptogenic activity of a novel withanolide -free aqueous fraction from the roots of *Withania somnifera* Dun. (Part II). *Phytother Res.* 2003;531-536.
19. Khare CP. *Indian Medicinal Plants—An Illustrated Dictionary.* First Indian Reprint, Springer (India) Pvt. Ltd., New Delhi. Kirtikar KR, Basu BD. *Indian Medicinal Plants* 2:717- 718; 2007.
20. Rastogi RP, Mehrotra BN. *Compendium of Indian Medicinal Plants.* 2nd Reprint, Central Drug Research Institute, Lucknow and National Institute of Science Communication, Council of Scientific and Industrial Research, New Delhi Vol. 1: 434-436; Vol. 2: 708-710; Vol. 3: 682-684; Vol. 4: 765-766; Vol. 5: 889-891; Vol. 6: 148, 1998.
21. Anabalagan K, Sadique J. *Withania somnifera*, a rejuvenating herbal drug which controls alpha-2 macroglobulin synthesis during inflammation. *Intl J Crude Drug Res.* 1985;23:177-183.
22. Bhattacharya SK; Muruganandam AV; Adaptogenic activity of *Withania somnifera*: an experimental study using a rat model of chronic stress. *Pharmacol Biochem Behav.* 2003;547-555.
23. Bhattacharya A, Ghosal S, Bhattacharya SK. Anti-oxidant effect of *Withania somnifera* glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. *J Ethnopharmacol.* 2001;74:1-6.
24. Mehta AK, Binkley P, Gandhi SS, Ticku MK. Pharmacological effects of *Withania somnifera* root extract on GABAA receptor complex *Indian J Med Res.* 1991;94: 312-15.
25. Archana R; Namasivayam A; Antistressor effect of *Withania somnifera*. *J Ethnopharmacol.* 1999;64:91-93.
26. Bhattacharya S, Goel R, Kaur R, Ghosal S. Antistress activity of sitoindosides VII and VIII, new acylsterylglucosides from *Withania somnifera* *Phytotherapy Res.* 1987;1:32-39.
27. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of *Withania somnifera*: an experimental study using a rat model of chronic stress. *Pharmacol Biochem Behav.* 2003;75:547-555.
28. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of *Withania somnifera* glycowithanolides: an experimental study. *Phytomed.* 2000;7:463-69.
29. Anonymous. *The Wealth of India.* Publications and Information Directorate, Council of Scientific and Industrial Research (CSIR), New Delhi; 580-85; 1982.
30. Dhuley JN. Effect of Aśgand on lipid peroxidation in stress induced animals. *J Ethnopharmacol.* 1998;7:173-178.
31. Anonymous. *The Wealth of India.* Publications and Information Directorate, Council of Scientific and Industrial Research (CSIR), New Delhi; 580-85; 1982.
32. SK Bhattacharya, KS Satyan, A Chakrabarti. Effect of Trasina, an Ayurvedic herbal formulation, on pancreatic islet superoxide dismutase activity in hyperglycaemic rats. *Indian J Exp Biol.* 1997;35(3):297-299.
33. Dhuley JN. Effect of ashwagandha on lipid peroxidation in stress-induced animals. *J Ethnopharmacol.* 1998; 60(2): 173-178.
34. Bhattacharya A, Ramanathan M, Ghosal S, Bhattacharya SK. Effect of *Withania somnifera* glycowithanolides on iron-induced hepatotoxicity in rats. *Phytother Res.* 2000;14(7):568-570.
35. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs.* Queensland, Australia: *Phytotherapy Press.* 1996: 137-41.
36. Kulkarni SK, George B. Anticonvulsant action of *Withania somnifera* root extract against pentylene tetrazole (PTZ)-induced convulsions in mice. *Phytotherapy Res.* 1996;95(10):447-449.
37. Kulkarni SK, Sharma A, Verma A, Ticku MK. GABA receptor mediated anticonvulsant action of *Withania somnifera* root extract. *Indian Drugs.* 1993;305-312.
38. Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal SV, Bigl. Systemic administration of defined extracts from *Withania somnifera* (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic And GABAergic markers in rat brain. *Neurochem Int.* 1997;30(2):181-190.
39. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C, Komatsu K. Withanolide derivatives from the roots of *Withania somnifera* and their neurite outgrowth activities. *Chem Pharm Bull Tokyo.* 2002;;50(6):760-65.
40. Naidu PS, Singh A, Kulkarni SK. Effect of *Withania somnifera* root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. *Phytother.* 2006;20(2):140-146.
41. Dhuley JN. Nootropic-like effect of ashwagandha (*Withania somnifera* L.) in mice. *Phytother.* 2001;15(6):524-28.
42. Kumar A, Kulkarni SK. Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice. *Indian J Exp Biol.* 2006;44(1):45-48.
43. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, et al. Neuroprotective effects of *Withania somnifera* on 6-hydroxydopamine Induced Parkinsonism in rats. *Hum Exp Toxicol.* 2005;24(3):137-147.
44. Naidu PS, Singh A, Kulkarni SK. Effect of *Withania somnifera* root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action. *J Med Food.* 2003;6(2):107-114.

45. Bhattacharya A, Bhattacharya D, Sairam K, Ghosal S. Effect of *Withania somnifera* glycowithanolides on a rat model of tardive dyskinesia. *Phytomed*. 2002;9(2):167-170.
46. Malhotra CL, Das PK, Dhalla NS, Prasad K. Studies on *Withania ashwagandha*, Kaul. III. The effect of total alkaloids on the cardiovascular system and respiration. *Indian J Med Sci*. 1981;49:448-460.
47. Mohanty I, Arya DS, Dinda A, Talwar KK, Joshi S, Gupta SK. Mechanisms of cardioprotective effect of *Withania somnifera* in experimentally induced myocardial infarction. *Basic Clin Pharmacol Toxicol*. 2004;94(4):184-190.
48. Ziauddin M, Phansalkar N, Patki P, Diwanay S, Patwardhan B. Studies on the immunomodulatory effect of *Withania somnifera*. *J Ethnopharmacol*. 1996;50(2):69-76.
49. Davis L, Kuttan G. Suppressive effect of cyclophosphamide-induced toxicity by *Withania somnifera* extract in mice. *J Ethnopharmacol*. 1998;62(3): 209-214.
50. Kuttan G. Use of *Withania somnifera* Dunal as an adjuvant during radiation therapy. *Indian J Exp Biol*. 1996;34(9):854-856.
51. Aggarwal R, Diwanay S, Patki P, Patwardhan B. Studies on immunomodulatory activity of *Withania somnifera* (Ashwagandha). *J App Pharm Sci*. 2012;2(1):170-175.
52. Bhattacharya SK, Satyan KS, Chakrabarti A. Effect of Transina (TR), an Ayurvedic herbal formulation, on pancreatic islet superoxide dismutase (SOD) activity in hyperglycaemic rats. *Indian J Exp Biol*. 1997;35(3): 297-299.
53. Visavadiya NP, Narasimhacharya AV. Hypocholesteremic and antioxidant Effects of *Withania somnifera* (Dunal) in hypercholesteremic rats. *Phytomed*. 2006 (In Press).
54. Hemalatha S, Wahi AK, Singh PN, Chansouria JP. Hypolipidemic activity of aqueous extract of *Withania coagulans* Dunal in albino rats. *Phytother Res*. 2006;20(7):614-17.
55. Andallu B, Radhika B. Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (*Withania somnifera*, Dunal) root. *Indian J Exp Biol*. 2000;38(6):607-09.
56. Ilayperuma I, Ratnasooriya RD, Weerasooriya TR. Effect of *Withania somnifera* root extract on the sexual behaviour of male rats. *Asian J Androl*. 2002;4(4):295-98.
57. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappa B-regulated gene expression. *Mol Cancer Therap*. 2006;1434-45.
58. Prakash J, Gupta SK, Dinda AK. *Withania somnifera* root extract prevents DMBA-induced squamous cell carcinoma of skin in Swiss albino mice. *Nutr Cancer*. 2002;42:91-97.
59. Jayaprakasam B, Zhang Y, Seeram N Nair. Growth inhibition of human tumor cell lines by withanolides from *Withania somnifera* leaves. *M. Life Sci*. 74: 125-32; 2003.
60. Singh N, Singh SP, Nath R et al. Ashwagandha:and its use with chemotherapy and radiation treatment. *Int J Crude Drug Res*. 1986;24:90-100.
61. Kulkarni RR, Patki PS, Jog VP et al. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. *J Ethnopharmacol*. 1991;33:91-95.
62. Angalagan K, Sadique J. *Indian J Exp Biol*, 1981;19:245-49.
63. Chaudhary G, Sharma U, Jagannathan N, Gupta Y. Evaluation of *Withania somnifera* in a middle cerebral artery occlusion model of stroke in rats. *Clin Exp Pharmacol Physiol*. 2003;30:399-404.
64. Bhattacharya SK, Bhattacharya D, Sairam K, Ghosal S. Effect of *Withania somnifera* glycowithanolides on a rat model of tardive dyskinesia. *Phytomed*. 2002;9:167-170.
65. Choudhary MI, Dur-e-Shahwar, Parveen Z et al. Ashwagandha:and its use. *Phytochem*. 1995;40:1243-46; 1995.